Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Clinical cure rates
RCT 6-armed trial	709 women with vulvovaginal candidiasis; analysis of 580 women, not by intention to treat (women with other vaginal infections excluded) In review	Persistent symptoms 30 days 31/95 (33%) with butoconazole 2% for 3 days (intravaginal cream) 31/96 (32%) with butoconazole 2% for 6 days (intravaginal cream) 34/95 (36%) with miconazole 2% for 3 days (intravaginal cream) 45/70 (64%) with placebo	P <0.03 for butoconazole 2% or miconazole v placebo	Effect size not calculated	intravaginal imidazoles
RCT 3-armed trial	95 women with clinically and mycologically confirmed vulvovaginal candidiasis; analysis of 90 women, not by intention to treat (see Further information on studies) In review	Persistent symptoms 4 weeks 6/20 (30%) with clotrimazole for 3 days (intravaginal tablets) 3/7 (43%) with placebo (oral)	Significance not reported
RCT	37 women with clinically and mycologically confirmed vulvovaginal candidiasis. Women in first trimester of pregnancy, women with diabetes or with other vaginal infections, and women using contraceptive foams or jellies were excluded	Persistent symptoms or mycological failure 27 to 38 days 4/18 (22%) with clotrimazole for 1 day (intravaginal tablet) 19/19 (100%) with placebo	P <0.0001	Effect size not calculated	intravaginal imidazoles